Skip to main content

Table 3 Utilization of drugs for OAD in MOC in comparison to Norway and Finland in 2010, in DDD/1000 inhabitants/day (DTID) and in percent of total use

From: Evaluation of pharmacotherapy of obstructive airway diseases in the Montenegrin outpatient care: comparison with two Scandinavian countries

Ord. No MOC 2010 Norway 2010 Finland 2009
  DTID (% of total use) DTID (% of total use) DTID (% of total use)
1. Fenoterol, ipratropium 6.11 (33.6 %) Salmeterol, corticosteroid 11.75 (18.4 %) Formoterol and other drugs for OAD 10.86 (18.6 %)
2. Salmeterol, fluticasone 3.41 (18.8 %) Salbutamol 11.32 (17.7 %) Salmeterol and other drugs for OAD 8.78 (15.0 %)
3. Aminophylline 2.43 (13.4 %) Ipratropium bromide 9.51 (14.9 %) Salbutamol 8.10 (13.9 %)
4. Fluticasone 1.98 (10.9 %) Formoterol, corticosteroid 8.43 (13.2 %) Fluticasone 5.49 (9.4 %)
5. Salbutamol 1.89 (10.4 %) Montelukast 4.70 (7.3 %) Budesonide 5.39 (9.2 %)
6. Salmeterol 1.45 (8.0 %) Tiotropium bromide 4.36 (6.8 %) Montelukast 5.16 (8.8 %)
7. Beclomethasone 0.41 (2.2 %) Fluticasone 3.11 (4.9 %) Tiotropium bromide 3.50 (6.0 %)
8. Theophylline 0.35 (1.9 %) Terbutaline 2.94 (4.6 %) Beclomethasone 3.27 (5.6 %)
9. Budesonide 0.15 (0.8 %) Budesonide 2.47 (3.9 %) Terbutaline 2.05 (3.5 %)
10. Othe 0.00 (0.0 %) Other 5.38 (8.4 %) Other 5.74 (9.8 %)
Total (R03) 18.18 (100.0 %) 63.97 (100.0 %) 58.34 (100.0 %)